louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06381206: Silodosin in Management of Lower Ureteral Stones
Official title: The Use of Selective Alpha Blockers (Silodosin) in Management of Lower Ureteral Stones Larger Than 6 mm in Diameter
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Stone, Kidney
Keywords: Silodosin
Lower Ureteral
Ureteral Stones
Lead sponsor: Syrian Private University
Sponsor class: OTHER
First posted: 2024-04-24
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research aims to study the effectiveness of silodosin in the management of lower ureter stones larger than 6 mm in diameter in terms of affected ureter (right or left), the size of the stone, the degree of hydronephrosis, the rate of stone expulsion(day), whether the stone was completely expelled or not, and the side effects of silodosin.


Eligibility criteria: Inclusion Criteria:

* Patients attending the urology Clinic with a distal unilateral ureteral stone larger than 6 mm in diameter.

Exclusion Criteria:

* Patients under 18 years of age
* Pregnant women
* Patients with whom we were unable to contact
* Patients treated with silodosin for another reason
* Single kidney patients
* Patients with bilateral ureter stones
* Patients with deteriorating kidney function
* Patients with grades 3rd and 4th of hydronephrosis

Primary outcomes:
measure: Stone expulsion (yes)
timeFrame: 1 year
measure: Stone expulsion (no)
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Damascus
country: Syrian Arab Republic
facility: Damascus university
Study officials:
References:
Clinical trial NCT01394406: Effect of Ketamine Added to Intravenous Patient-controlled Analgesia on Postoperative Pain, Nausea and Vomiting in Patients Undergoing Lumbar Spinal Surgery
Official title: Effect of Ketamine Added to Intravenous Patient-controlled Analgesia on Postoperative Pain, Nausea and Vomiting in Patients Undergoing Lumbar Spinal Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Nausea and Vomiting
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2011-07-14
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Ketamine added to intravenous patient-controlled analgesia may be effective on prevention of postoperative nausea and vomiting by reducing opioid requirement after surgery.


Eligibility criteria: Inclusion Criteria:

* Non-smoking female patients undergoing elective lumbar spinal surgery
* Age 20-65
* American Society of Anesthesiologists physical status classification I or II

Exclusion Criteria:

* Antiemetic within 24 hrs, Taking Steroids, Opioids within 1 week
* Psychiatric disease, Active drug or alcohol abuse
* GI motility disorder, severe renal/ hepatic disease
* insulin-dependent DM
* admission to ICU after surgery

Primary outcomes:
measure: Incidence of postoperative nausea and vomiting
timeFrame: within 48 hrs after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
Clinical trial NCT06132906: Comparison Between Two Techniques to Reposition the Maxilla After le Fort 1
Official title: Comparison of Accuracy Between Novel Locating Guide Design With Pre-bent Titanium Plates and 3d Printed Intermediate Wafer to Reposition the Maxilla After le Fort 1 Osteotomy in Orthognathic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dentofacial Deformities
Le Fort; I
Keywords: orthognathic
virtual planning
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2023-11-15
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: clinical and radiographic comparison between novel locating guide design with pre-bent titanium plates and 3d printed intermediate wafer to reposition the maxilla after Le Fort 1 osteotomy in orthognathic surgery (randomized controlled clinical trial)

Detailed description: Eligible patients will be allocated randomly into 2 equal groups with 7 patients in each group according to the method that will be used to reposition the maxilla by simple randomization using computer generated random numbers. Group 1 (Study group) will be treated with locating guides to reposition the maxilla with pre-bent plates on 3d model. Group 2 (Control group) will be treated with Intermediate wafer.

Eligibility criteria: Inclusion Criteria:

* All patients requiring Le Fort I osteotomy will be selected including those suffering from skeletal malocclusion (Class II or Class III), midface hypoplasia or vertical maxillary excess.

Exclusion Criteria:

cleft lip and palate. skeletal disharmony due to trauma or severe facial asymmetry. significant medical condition.

Primary outcomes:
measure: Radiographic evaluation of accuracy by superimposition
timeFrame: 2 weeks
measure: The surgery duration
timeFrame: 1 week
Secondary outcomes:
measure: Postoperative Pain
timeFrame: after one week, two weeks
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria University, Faculty of dentistry
Study officials:
References:
Clinical trial NCT00770406: Intravesical Instillation of Botulinum Toxin Type A to Patients With Urge Urinary Incontinence
Official title: Intravesikal Instillation af Botulinum Toxin Type A Til Patienter Med Urge Urininkontinens
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Urge Urinary Incontinence
Lead sponsor: Glostrup University Hospital, Copenhagen
Sponsor class: OTHER
First posted: 2008-10-10
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A pilot study to examine efficacy and safety of intravesical botulinum toxin type A.


Eligibility criteria: Inclusion Criteria:

* refractory urge urinary incontinence

Exclusion Criteria:

* neurological disease
* pregnant or lactating
* bladder neoplasias

Primary outcomes:
measure: Incontinence episode frequency
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Glostrup Hospital
state: Copenhagen
Study officials:
References:
Clinical trial NCT00617006: Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice
Official title: Before and After Study Evaluating Deployment of the Sprixx GJ Personal Hand Hygiene Device in the Intra-Operative Environment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nosocomial Infections
Keywords: Anesthesia Workspace
Hospital Acquired Infections
Hand Hygiene
Alcohol Based Cleanser
Bacterial Contamination
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: Harbor Medical Inc.
First posted: 2008-02-15
Enrollment: 114
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Operating Rooms were randomized and patients in these rooms were enrolled for the study.

Brief summary: We hypothesized that by improving hand hygiene compliance in the operative environment, we would reduce horizontal transmission of pathogenic bacteria to surgical patients.

Detailed description: We performed an observational study evaluating provider adherence to these techniques. We then sought to increase hand hygiene compliance through the use of a point of care alcohol based hand hygiene device. We hypothesized that increased hand hygiene compliance would reduce bacterial contamination of the anesthesia workspace and peripheral intravenous tubing, and ultimately reducing overall morbidity and mortality secondary to a reduction in nosocomial infection rates.

Eligibility criteria: Inclusion Criteria:

* Patients present in operating rooms randomized to study.

Exclusion Criteria:

* Patients that were already enrolled in study and return to the operating room.

Primary outcomes:
measure: The presence of a positive culture on the previously sterile patient stopcock set, and the presence of multidrug resistant bacteria
timeFrame: Beginning and end of surgical case
Secondary outcomes:
measure: Reduction of bacterial contamination on predetermined sites on the anesthesia machine
timeFrame: Beginning and End of Surgical Case
measure: Decreased length of stay
timeFrame: Postoperatively
measure: Nosocomial infection rates
timeFrame: within 30 days postoperatively
measure: Mortality
timeFrame: Within 30 days postoperatively
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchocck Medical Center
name: Matthew D Koff, M.D. M.S.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Koff MD, Loftus RW, Burchman CC, Schwartzman JD, Read ME, Henry ES, Beach ML. Reduction in intraoperative bacterial contamination of peripheral intravenous tubing through the use of a novel device. Anesthesiology. 2009 May;110(5):978-85. doi: 10.1097/ALN.0b013e3181a06ec3.
Clinical trial NCT03856606: The Effects of Interrupting Prolonged Sitting With Intermittent Exercise on Postprandial Lipemia
Official title: The Effects of Interrupting Prolonged Sitting With Intermittent Exercise on Postprandial Lipemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Metabolic Syndrome X
Atherosclerosis
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Disease
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lead sponsor: University of Texas at Austin
Sponsor class: OTHER
First posted: 2019-02-27
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate the effect of interrupting prolong sedentary behavior with interval exercise on postprandial metabolism following a high fat glucose tolerance test.

Detailed description: All subjects complete two trials in a randomized crossover design, with each trial occurring over 4 days with a minimum of seven days between trials. The first two days of each trial serve as a control period allowing for familiarization and the control of physical activity and calorie consumption prior to the intervention. Following each control period, subjects then perform one of the interventions on Day 3. The interventions consist of either eight-hours of prolonged sitting, or eight hours of sitting interrupted every hour by five sprints lasting 4 seconds each using the interval exercise. On day 4, all subjects will undergo a high fat glucose tolerance test to determine the body's ability to clear triglycerides from the blood as well as insulin/glucose response and substrate oxidation. Blood samples will be assayed for the previously mentioned substances and postprandial gas collection will be analyzed via indirect calorimetry.

Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

* cardiovascular problems (e.g. pre-existing heart issues, coronary artery disease, hypertension, etc.)
* respiratory problems
* musculoskeletal problems that prevent prolonged sitting or exercise
* susceptibility to fainting
* Pregnancy

Primary outcomes:
measure: Plasma Triglycerides
timeFrame: 6-hours
Secondary outcomes:
measure: Plasma Insulin
timeFrame: 6-hours
measure: Plasma Glucose
timeFrame: 6-hours
Other outcomes:
Locations:
city: Austin
country: United States
facility: University of Texas at Austin Human Performance Laboratory
state: Texas
Study officials:
affiliation: University of Texas at Austin
name: Edward F Coyle, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06214806: Food Is Medicine: Makin' Healthy Groceries
Official title: Impact of a Food Purchasing Intervention on Consumption Patterns and Improved Dietary Outcomes in New Orleans - Food Is Medicine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Keywords: Food Insecurity
Food As Medicine
American Heart Association (AHA)
New Orleans
Louisiana
PCORnet
Electronic Health Record (EHR)
Cardiovascular Disease
Hypertension
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: American Heart Association
name: Rouses Market
name: Instacart
name: Duke Clinical Research Institute
name: University Medical Center New Orleans - LCMC Health
name: Louisiana Public Health Institute
First posted: 2024-01-22
Enrollment: 97
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Food delivered via Instacart versus comparator arm of food purchased in-person at Rouses Market
Primary purpose: TREATMENT

Brief summary: This is a minimal risk study focusing on food purchasing and consumption in 100 subjects in the greater New Orleans area. There is evidence showing that individually-targeted vouchers effectively increase category-level food purchases in both less healthful and more healthful categories. This pilot study will investigate whether a voucher program using Instacart or a local, brick-and-mortar supermarket in New Orleans, LA lead to changes in food purchasing patterns, food consumption, food insecurity, and access to healthy food options for the participants, who are at risk of cardiovascular disease and/or cardiac complications. The study will also measure concordance between food purchasing and actual consumption.


Eligibility criteria: Inclusion Criteria:

* Greater than or equal to 50 years of age
* Uncontrolled hypertension (defined as at least two clinically documented blood pressure readings of systolic BP \>= 140 AND diastolic BP \>=90 in the prior 6 months)
* Understands English

Exclusion Criteria:

* No internet access (at home, library, relative, or though phone plan)
* No adequate transportation (personal car, reliable ride, bus, and/or Uber/Lyft) in the New Orleans area

Primary outcomes:
measure: Change in food consumption
timeFrame: Baseline, every month for 5 months
Secondary outcomes:
measure: Change in food purchasing
timeFrame: Every month, between months 1-5
measure: Use of voucher
timeFrame: Every month, between months 1-5
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: University Medical Center New Orleans - LCMC Health
state: Louisiana
city: New Orleans
country: United States
facility: Louisiana Public Health Institute (LPHI)
state: Louisiana
Study officials:
affiliation: Duke Clinical Research Institute
name: Adrian Hernandez, MD, MHS
role: PRINCIPAL_INVESTIGATOR
affiliation: Louisiana Public Health Institute (LPHI)
name: Thomas W Carton, PhD, MS
role: STUDY_DIRECTOR
affiliation: Louisiana Public Health Institute (LPHI)
name: Bridget Simon-Friedt
role: STUDY_CHAIR
References:
Clinical trial NCT00086606: A Safety and Efficacy Study of Xolair in Peanut Allergy
Official title: A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Oral Food Challenge Trial of Xolair (Omalizumab) in Peanut Allergy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Allergy
Keywords: Peanut
Lead sponsor: Genentech, Inc.
Sponsor class: INDUSTRY
First posted: 2004-07-09
Enrollment: 150
Sex: ALL
Minimum age (years): 6
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.


Eligibility criteria: Inclusion Criteria:

* The patient has a diagnosis of acute peanut allergy
* The patient meets the Xolair dosing table eligibility criteria by having a serum baseline IgE level between 30 and 1300IU/mL, and a body weight between 20 and 150 kilograms
* The patient is six to 75 years of age
* The patient reacts to peanut flour but not wheat (placebo) flour during the first Oral Food Challenge (OFC)
* The patient has a positive skin prick test to peanut or detectable serum peanut-specific IgE level
* The patient is able to swallow capsules

Exclusion Criteria:

* Have FEV1 value \<80% predicted or any clinical features of moderate persistent asthma, as defined by the NHLBI guidelines
* Have other significant medical conditions (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders), which, in the opinion of the Investigator, make the subject unsuitable for induction of food reactions
* Have a history of allergy to wheat protein
* Have previously been exposed to monoclonal antibody treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Trial Information Support Line
state: Colorado
Study officials:
affiliation: Genentech, Inc.
name: Yamo Deniz, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06010706: Supervised Manual Physical Therapy Exercise for Ankle Disability After Motor Vehicle Accidents.
Official title: Efficacy of Supervised Manual Physical Therapy Exercise for Ankle Disability After Motor Vehicle Accidents, Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ankle Deformity
Lead sponsor: Jouf University
Sponsor class: OTHER
First posted: 2023-08-24
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Every year more than 50 million people worldwide are injured due to RTAs which in turn makes it one of the leading causes of disability. During automobile collisions, the lower limbs are the most commonly injured region of the human body. Ankle injuries can be particularly long-lasting, resulting in excessive medical costs, inability to work, and serious psychological distress. Physiotherapists often contribute to the rehabilitation of ankle fractures, which typically starts soon after the period of immobilization. Joint mobilization led to increased ankle movement, improved gait patterns, reduced pain and the number of treatment sessions required, and hastened return to activities when compared with the usual rest, ice, compression, and elevation protocol.

Detailed description: Participants will be assigned into two groups:

1. Study group will receive a Supervised physical therapy exercise program in the form of Mobilization exercise, Stretching exercise, and Strengthening exercise.
2. Control group will receive a Home-based exercise program of Stretching exercises, strengthening exercises and ROM exercises.

Eligibility criteria: Inclusion Criteria:

* Patients with Stable ankle fractures after motor vehicle accidents involving the distal tibia, distal fibula, or talus treated with cast immobilization, with the removed cast in the preceding seven days.
* Approval from the orthopedic specialist to weight-bear as tolerated or partial weight-bear. -- Their ages will be between the age of 18 to 50 years of age.
* Participants having no concurrent injuries or pathology, such as neurological injury or other fractures.

Exclusion Criteria:

* Patients with surgical fixation,
* Fracture malunion or nonunion,
* Syndesmosis injury, or any standard contraindication to manual physical therapy.

Primary outcomes:
measure: 1. EMG assessment of muscle activity:
timeFrame: 2 momths
Secondary outcomes:
measure: Dynamic Plantar Pressure
timeFrame: 2 months.
measure: Berg Balance Scale (BBS):
timeFrame: 2 months.
measure: Ankle Joint Dorsiflexion and Planterflexion Range (ROM):
timeFrame: 2 months.
measure: Pain Assessment.
timeFrame: 2 months.
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Hadaya Mosaad Eladl
Study officials:
References:
Clinical trial NCT00574106: A Study to Evaluate the Effect of Far Infrared Radiation for Cancer Treatment
Official title: Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation for Cancer Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Neoplasms
Keywords: Cancer
Tumors
Lead sponsor: GAAD Medical Research Institute Inc.
Sponsor class: OTHER
First posted: 2007-12-14
Enrollment: 3
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Cancer is the number one killer in Canada and in most countries of the world. The investigators' initial assessment indicates that far infrared radiation has the potential to cure cancer.

Detailed description: The investigators have identified a combination of methods for possible cancer treatment as follows:

1. Energy specific far infrared radiation (5 μm to 20 μm ). No x-rays, gamma rays etc. are used.
2. Oxygenation of the body cells
3. pH balance
4. Lifestyle changes, or
5. A combination of chemotherapy and (1), (2), (3) and (4) above.

Eligibility criteria: Inclusion Criteria:

* All cancer patients

Exclusion Criteria:

* non-cancer patients

Primary outcomes:
measure: The effect of far infrared radiation on cancerous tumours
timeFrame: 1 year
Secondary outcomes:
measure: The effect on far infrared treatment on different kinds of cancer.
timeFrame: 1 year
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Centre for Incurable Diseases
state: Ontario
Study officials:
affiliation: GAAD Medical Research Institute Inc.
name: Ken Nedd, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: GAAD Medical Research Institute Inc.
name: Kwasi Donyina, Ph.D.
role: STUDY_DIRECTOR
References: